CASE REPORT article
Front. Immunol.
Sec. Autoimmune and Autoinflammatory Disorders : Autoimmune Disorders
Efgartigimod Combined with Rituximab Helps the Symptoms Improvement and the Reduction in Corticosteroids in MUSK Antibody-Positive MG Patients: A Single Case Report
Provisionally accepted
- 1汕头市中心医院, 汕头市, China
- 2中山大学附属第一医院, 广州市, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Abstract Introduction: Myasthenia gravis (MG) is an autoimmune disorder primarily affecting the neuromuscular junction. Muscle-specific receptor tyrosine kinase antibody (MuSK-Ab) mediated MG often presents with bulbar weakness and is prone to crisis. Currently, conventional treatments show limited efficacy in MuSK-Ab mediated MG, while rituximab therapy demonstrates favorable outcomes. Case presentation: We report a case of a patient who initially achieved symptom control with efgartigimod during an acute exacerbation but experienced symptom recurrence after subsequent rituximab treatment. Due to poor tolerance to pyridostigmine and corticosteroids, and considering the established efficacy of efgartigimod in MuSK-Ab positive MG, we opted for continued efgartigimod infusions. This approach quickly improved symptoms, achieved minimal symptom expression (MSE), and allowed faster tapering of corticosteroids and pyridostigmine. Conclusion: While multiple studies have demonstrated the efficacy and safety of efgartigimod, large-scale studies remain necessary to further evaluate the feasibility of combination therapy with rituximab in MuSK-Ab positive MG.
Keywords: Myasthenia gravis (MG), Musk, efgartigimod, rituximab, case report
Received: 28 Sep 2025; Accepted: 08 Dec 2025.
Copyright: © 2025 郑, 王, 蔡 and 周. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: 秀君 郑
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.